Pipeline
Our Approach
Our Selective Endocannabinoid Reuptake Inhibitors (SERIs) target the endocannabinoid membrane transporter, a newly identified protein within the endocannabinoid system (ECS). SERIs restore and gently increase endocannabinoid levels which are dysregulated under pathologically conditions. This self‑limiting mechanism underpins physiological balance rather than overstimulation, aiming to rebalance brain networks involved in emotion, cognition and stress regulation.
Development Strategy
SERIs offer an innovative, potentially better‑tolerated approach for disorders driven by anxiety, mood and stress‑related dysregulation, complementing or improving upon existing treatments. By restoring the 'endocannabinoid tone', these medicines seek to improve daily functioning and quality of life for patients who do not adequately respond to current standards of care.
Synendos concentrates on symptom domains that cut across diagnoses, such as anxiety, seizures and involuntary movements, where endocannabinoid modulation shows strong therapeutic promise.
Anxiety symptoms are a core focus. They are prevalent in conditions like Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD) and Post‑Traumatic Stress Disorder (PTSD), and are often insufficiently controlled by available therapies.
Our strategy focuses on carefully selected symptom domains and indications with the potential to transform neuroscience care and substantially improve the lives of millions of patients. Synendos is pioneering the way by being first in a new class of therapeutics targeting the endocannabinoid system (ECS).
Lead Candidate SYT-510 & Other ECS Modulators
Our lead candidate, SYT-510, which successfully completed preclinical and Phase 1 studies, will be evaluated in a Phase 2a study in patients with GAD. This will pave the way for future studies in anxiety-related conditions such as PTSD.
Our next-generation SERI, SYT-550, has completed lead optimization and is ready to enter IND-enabling studies to target other neuropsychiatric conditions. We also have several additional SERIs and alternative ECS modulators in early development.